Page 1,785«..1020..1,7841,7851,7861,787..1,7901,800..»

DSU AgDiscovery 2015 – Investing in the Future of American …

Posted: June 1, 2015 at 11:44 pm

DELAWARE STATE UNIVERSITY JULY 619, 2015 Learn about the business aspects of protecting plants and animals while exploring careers in agribusiness. Students will live on the Delaware State University (DSU) campus in Dover and learn about a variety of administrative professions from university professors and agriculture employees. Contact: Harry Thayer, (302) 857-6434, hthayer@desu.edu http://www.desu.edu DSU, founded in 1891 as the State College for Colored Students, takes pride in its heritage as one of the countrys first land-grant educational institutions, rooted early on in agriculture and education. DSUs current population includes a 76-percent African American enrollment and an increasing number of Caucasian, Hispanic, Asian, and other international students.

ARE YOU... a middle or high school student looking for a unique summer internship with an opportunity to live and study on a college campus? a high school student looking to improve your resume for college? a teacher looking for opportunities to expand your students view of agriculture? a parent looking for learning opportunities for your teen? Look no further the U.S. Department of Agriculture (USDA) offers you an opportunity of a lifetime. WHAT IS AGDISCOVERY? AgDiscovery is a summer outreach program to help teenagers learn about careers in plant and animal science, wildlife management, and agribusiness. The program allows students to live on a college campus and learn about agriculture from university professors, scientists, and administrative professionals who work for the U.S. Government in a variety of fields. They study the life cycles and habits of insects (entomologists); research micro-organisms, such as bacteria and viruses (biotechnologists); examine cells and tissues under a microscope to identify diseases (plant pathologists); work to conserve and manage wild animals and their habitats (wildlife biologists); carry out animal health programs (veterinarians); provide education on the humane care and treatment of animals (veterinarians and animal care inspectors); and manage the business aspects of protecting plants and animals (agribusiness). This 2- to 4-week summer outreach program for 2015 targets middle and high school students1 who are interested in learning more about plants, animals, and agribusiness. Students chosen to participate in AgDiscovery will gain experience through hands-on labs, workshops, and field trips. Students will also participate in character- and team-building activities and a variety of workshops.

WHO SPONSORS AGDISCOVERY? USDAs Animal and Plant Health Inspection Service (APHIS) partners with various universities and colleges to deliver the AgDiscovery program. Many of the Federal Governments professional plant scientists, biotechnologists, veterinarians, and wildlife biologists work for APHIS. The agency funds AgDiscovery each year, and partner universities host program participants on their local campuses. In 2015, there are 17 universities participating in AgDiscovery: Alcorn State University, Delaware State University, Florida Agricultural and Mechanical University, Fort Valley State University, Iowa State University, Kentucky State University, Lincoln University in Missouri, North Carolina State University, South Carolina State University, Tuskegee University, University of Arizona, University of Arkansas at Pine Bluff, University of Hawaii at Manoa, University of Illinois at Urbana-Champaign, University of Maryland at College Park, University of Maryland Eastern Shore, and Virginia State University. Each universitys AgDiscovery program focuses on a specific area of interest to our Nations agriculture, such as plant health, entomology, veterinary science, animal care, biotechnology, and agribusiness. AgDiscovery is a unique opportunity for students to gain a first-hand look at the many career paths open to them in the agricultural sciences. For those interested in an agricultural career, AgDiscovery is a great way to get started. Read on to learn more about this years program, including dates, locations, cost information, eligibility, and how to apply.

http://www.aphis.usda.gov/publications/aphis_general/2014/bro_ag_discove...

Excerpt from:
DSU AgDiscovery 2015 - Investing in the Future of American ...

Posted in Delaware Stem Cells | Comments Off on DSU AgDiscovery 2015 – Investing in the Future of American …

Stem cells, Darth Vader and the high cost of hope and hype …

Posted: June 1, 2015 at 11:44 pm

Darth Vader: Photo by Stefano Buttafoco

Its not very often that you get stories about stem cells that mention Darth Vader, Obi Wan Kenobi, the Pittsburgh Steelers and a Beverly Hills plastic surgeon, but those references all popped up in a recent flurry of articles that are shining yet again the light on many of the unproven, unregulated uses of stem cells to treat everything from arthritis to Parkinsons disease.

Lets start with an article by Associated Press (AP) writer Will Graves who digs into the use of stem cells in sports. Graves does a good job of highlighting all the reasons why an athlete would try a stem cell therapy quoting Dr. Jim Bradley, a team physician with the Steelers:

They want the cutting edge, anything that is cutting edge that can get their guys a couple more years in the league. If I was an agent, Id want the same thing.

But Graves also does a fine job of pointing out that these therapies are unproven, and that in many cases athletes go overseas to get them because those clinics do not have to meet the same strict regulations as clinics here in the US.

Traveling to a place like the Caymans, thats like saying Im going to Mexico to have an appendectomy to save $80,' said Dr. Matthew Matava, head physician for the St. Louis Rams and the NHLs St. Louis Blues. It looks like its not very smart or youre grasping at straws.

He also quotes Dr. Freddie Fu, head physician for the University of Pittsburgh athletics program, saying there is far too much uncertainty to take risks. Fu says in many cases the people delivering the therapies dont even know where these stem cells might go, or what they might do:

You can have one cell be Obi Wan Kenobi, the other is Darth Vader. Youre not sure which way its going to go.

Matthew Perrone starts his piece in the Huffington Post, with a paragraph that is both gripping and disgusting:

The liquid is dark red, a mixture of fat and blood, and Dr. Mark Berman pumps it out of the patients backside. He treats it with a chemical, runs it through a processor and injects it into the womans aching knees and elbows.

Read the rest here:
Stem cells, Darth Vader and the high cost of hope and hype ...

Posted in California Stem Cells | Comments Off on Stem cells, Darth Vader and the high cost of hope and hype …

Asymmetrex Will Discuss the Importance of Adult Tissue …

Posted: June 1, 2015 at 11:43 pm

Congregants attending the Applying 3D Models for Toxicological Research conference at the 14th Annual World Preclinical Congress (WPC), from June 10-12 in Boston, are anticipating an important new emphasis for tissue stem cell engineering of drug development platforms. At the Congress, tissue stem cell biotechnology start-up Asymmetrex will present its unique emphasis on what it calls the third dimension of time, which applies to its new technology for early detection of drug candidates that are likely to fail later because of poorly tolerated toxicity against adult tissue stem cells.

Boston, MA (PRWEB) May 28, 2015

In two different WPC forums, Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D., will present the companys unique approach to developing technologies for stem cell medicine. In a conference talk, he will describe Asymmetrexs innovation in integrating its proprietary stem cell culture designs with computer simulation to produce the first-ever technology for quantitative monitoring of adult tissue stem cell number and quality over time in culture. When leading an interactive breakout discussion group, Sherley will discuss with 3D tissue engineers how the tissue biology time principles that inspire Asymmetrexs technology might improve their engineered artificial tissue systems developed for use in pharmaceutical drug testing.

3D tissue engineering has the goal of developing facsimiles of normal or diseased human tissues that are more accessible and efficient for discovering and evaluating new therapeutic drugs. Human cell cultures in plastic petri dishes are called 2D systems, because they lack the higher dimension of cell architecture and connecting materials that constitute tissues in the body. In two weeks, at the 14th WPC, 3D tissue engineers interested in developing better tests for drug safety will convene to give special attention to new concepts and approaches for incorporating natural 3D properties into engineered 3D systems.

As disclosed by Sherley in a recent pre-congress interview, Asymmetrex is not a typical 3D tissue engineering company. Instead, its technology is based on specific attention to the dimension of time in 2D cultures containing human adult tissue stem cells. In collaboration with its partner, AlphaSTAR Corporation, Asymmetrex has integrated computer simulation with principles of the special manner in which tissue stem cells multiply over time in simple 2D cultures. Their resulting AlphaSTEM technology provides the ability to identify compounds that are tissue stem cell-toxic, for the first time, before employing animals in preclinical studies or human volunteers in Phase I clinical trials to evaluate drug safety.

In his conference talk, Sherley will describe the new AlphaSTEM technology and update progress on its technical and commercial development. Asymmetrex has studies under way to evaluate the predictive power of AlphaSTEM with panels of drugs of known toxicity against human adult tissue stem cells. Asymmetrex and AlphaSTAR have recently begun marketing their prototype technology to large and mid-range pharmaceutical companies for alpha testing. About 10% of new drug candidates are estimated to fail in preclinical animal testing or clinical trials because of adult tissue stem cell toxicity. By detecting these future failures earlier in the pipeline, AlphaSTEM technology is projected to accelerate drug development, reduce its cost, and improve drug safety. With widespread use, AlphaSTEM could reduce U.S. drug development costs by $4-5 billion each year.

In his interactive breakout presentation, Sherley plans to discuss how the same third dimension of time principles are important in traditional 3D tissue engineering towards building drug testing systems that are more faithful to the properties of tissues in the body. In many organs and tissues in the body, cell multiplication and movement occur continuously. However, although current tissue engineering strategies are well-focused on mimicking physical 3D features, they largely overlook crucial features related to time like tissue stem cell dynamics. By learning about the essential role of tissue stem cell time in Asymmetrexs 2D AlphaSTEM technology, Sherley hopes that 3D tissue engineers will be inspired to consider its value in their efforts to engineer better 3D tissue systems for drug evaluations.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrexs focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

For the original version on PRWeb visit: http://www.prweb.com/releases/2015/05/prweb12751696.htm

Read this article:
Asymmetrex Will Discuss the Importance of Adult Tissue ...

Posted in Arkansas Stem Cells | Comments Off on Asymmetrex Will Discuss the Importance of Adult Tissue …

Washington DC Stem Cells – Dr. Lox Stem Cells

Posted: June 1, 2015 at 11:43 pm

Each week, Dr. Dennis Lox receives inquiries from around the world regarding stem cell therapy.

Many patients are turning to stem cell therapy as a means of nonsurgical joint pain relief when their mobility and quality of life are severely affected by conditions like osteoarthritis, torn tendons, and injured ligaments. Dennis M. Lox, M.D. specializes in this progressive, innovative treatment that may be able to help you return to an active, fulfilling life.

Since 1990, Dennis M. Lox, M.D. has been helping patients increase their quality of life by reducing their pain. He emphasizes non-surgical treatments and appropriate use of medications, if needed.

Dr. Dennis Lox an expert in Stem Cell Therapy for knee osteoarthritis and sports injuries, and Dr. Lox has treated numerous international patients with knee OA at his Tampa Bay, Florida clinic, as the growing trend to see the top stem cell physicians in the United States grows with international patients. Each week Dr. Dennis Lox is consulted by a growing number of international patients for a variety of problems besides just the knee for Stem Cell Therapy. As a result Dr. Lox has opened an office in the Washington D. C./ Northern Virginia area to treat International patients with stem cells as travel to the Washington D. C. airports has greater accessibility. Knee osteoarthritis is a common problem with aging. Traditional therapies used to treat osteoarthritis fail to halt the progression of arthritis. This is a frustrating situation for patients. The emergence of regenerative medicine and stem cell treatments for osteoarthritis has become more popular. The appeal of stem cells is that they may differentiate into other cells needed for the repair process of arthritis such as cartilage, bone and muscle cells. This reparative effect is ideal for the situation in which traditional therapies such as arthritis medications and cortisone injections do not alter the progression of osteoarthritis.

Stem cells are also potent anti-inflammatory and immune regulating cells which may reduce the pain and swelling associated with inflammation. The knee is a frequently injured joint and the leading joint with arthritis. Dr. Lox utilizes stem cells to treat international patients with knee disorders ranging from those experiencing arthritis to the professional athlete.

Read more:
Washington DC Stem Cells - Dr. Lox Stem Cells

Posted in Washington Stem Cells | Comments Off on Washington DC Stem Cells – Dr. Lox Stem Cells

Director Molecular Genetics jobs in Rtp at LabCorp

Posted: June 1, 2015 at 6:41 am

Job Code: 41195

Location: Rtp, NC

Category: Lab Jobs

The position requires a Ph.D. in Genetics or a related field, ABMG certification or active candidate status in Clinical Molecular Genetics.

Job Description:

LabCorp is seeking a Clinical Molecular Geneticist (title dependent on experience) to join a team of directors in our Molecular Genetics Laboratory at the Center for Molecular Biology and Pathology (CMBP) located in Research Triangle Park, North Carolina. The laboratory is a state-of-the-art, high throughput molecular facility. The directors oversee a diverse menu of targeted mutation and sequencing analyses, including whole exome sequencing and non-invasive prenatal testing. The laboratory works in close concert with cytogenetics, molecular oncology, and biochemical genetics at CMBP and is supported by a team of genetic counselors. The position requires a Ph.D. in Genetics or a related field. ABMG (or equivalent) certification or active candidate status is required in Clinical Molecular Genetics.

About LabCorp

Laboratory Corporation of America Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.8 billion in 2013, over 34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technology through its LabCorp Specialty Testing Group: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc, The Center for Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated Oncology, Dianon Pathology, Monogram Biosciences, Inc, Colorado Coagulation, Cellmark Forensics, MedTox, and Endocrine Sciences. LabCorp conducts clinical trials testing through its LabCorp Clinical Trials division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our website at: http://www.labcorp.com.

The 7,000-acre Research Triangle Park is the largest research park in the United States, and is home to over 140 organizations (Biotechnology, Pharmaceuticals, Healthcare, and Information Technology / Telecommunications) and has around 45,000 full time employees entering the Park each day. The Research Triangle itself is named for the Triangle formed by the three universities: Duke University at Durham, the University of North Carolina at Chapel Hill, and North Carolina State University in Raleigh.

Read more:
Director Molecular Genetics jobs in Rtp at LabCorp

Posted in Molecular Genetics | Comments Off on Director Molecular Genetics jobs in Rtp at LabCorp

T Cell Therapy (CTL019) | The Children's Hospital of …

Posted: June 1, 2015 at 6:40 am

CTL019 is a clinical trial of T cell therapyfor patients with B cell cancers such as acute lymphoblastic leukemia (ALL), B cell non-Hodgkin lymphoma (NHL), and the adult disease chronic lymphocytic leukemia (CLL). At this time, The Children's Hospital of Philadelphia is the only hospital enrolling pediatric patientson this trial.

In July 2014, CTL019 was awarded Breakthrough Therapy designation by the U.S. Food and Drug Administration for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). The investigational therapy is the first personalized cellular therapy for the treatment of cancer to receive this important classification.

In this clinical trial, immune cells called T cells are taken from a patient's own blood. These cells are genetically modified to express a protein which will recognize and bind to a target called CD19, which is found on cancerous B cells. This is how T cell therapy works:

30 patients with acute lymphoblastic leukemia (25 children and 5 adults) have been treatedusing T cell therapy.Of those patients:

The most recent results were published in The New England Journal of Medicine in October 2014. Scientists at The Childrens Hospital of Philadelphia and the University of Pennsylvania are very hopeful that CTL019 could in the future be an effective therapy for patients with B cell cancers. However, because so few patients have been treated, and because those patients have been followed for a relatively shorttime,it is critical that more adult and pediatric patients are enrolled in the study to determine whether a larger group of patients with B cell cancers will have the same response, and maintain that response.

At this point CHOP's capability to enroll patients is limited because of the need to manufacture the T cell product used in this therapy. Our goal is to boost enrollment soon, by increasing our manufacturing capabilities and by broadening this study to other pediatric hospitals.

T cell therapy is a treatment for children and adolescents with fairly advanced B cell acute lymphoblastic leukemia (ALL) and B cell lymphomas, but not other leukemias or pediatric cancers. It is an option for those patients who have very resistant ALL.

Roughly 85 percent of ALL cases are treated very successfully with standard chemotherapy. For the remaining 15 percent of cases, representing a substantial number of children in the United States, chemotherapy only works temporarily or not at all. This is not a treatment for newly diagnosed leukemia, only for patients whose leukemia is not responding to chemotherapy,and whose disease has come back after a bone marrow transplant.

It is important to note that while results of this study are encouraging, it is still very early in testing and that not all children who qualify for the trial will have the same result.

See more here:
T Cell Therapy (CTL019) | The Children's Hospital of ...

Posted in Cell Therapy | Comments Off on T Cell Therapy (CTL019) | The Children's Hospital of …

Stem Cells In Use – Learn Genetics

Posted: May 31, 2015 at 5:41 pm

In 1968, doctors performed the first successful bone marrow transplant. Bone marrow contains somatic stem cells that can produce all of the different cell types that make up our blood. It is transplanted routinely to treat a variety of blood and bone marrow diseases, blood cancers, and immune disorders. More recently, stem cells from the blood stream (called peripheral blood stem cells) and umbilical cord stem cells have been used to treat some of the same blood-based diseases.

Leukemia is a cancer of white blood cells, or leukocytes. Like other blood cells, leukocytes develop from somatic stem cells. Mature leukocytes are released into the bloodstream, where they work to fight off infections in our bodies.

Leukemia results when leukocytes begin to grow and function abnormally, becoming cancerous. These abnormal cells cannot fight off infection, and they interfere with the functions of other organs.

Successful treatment for leukemia depends on getting rid of all the abnormal leukocytes in the patient, allowing healthy ones to grow in their place. One way to do this is through chemotherapy, which uses potent drugs to target and kill the abnormal cells. When chemotherapy alone can't eliminate them all, physicians sometimes turn to bone marrow transplants.

In a bone marrow transplant, the patient's bone marrow stem cells are replaced with those from a healthy, matching donor. To do this, all of the patient's existing bone marrow and abnormal leukocytes are first killed using a combination of chemotherapy and radiation. Next, a sample of donor bone marrow containing healthy stem cells is introduced into the patient's bloodstream.

If the transplant is successful, the stem cells will migrate into the patient's bone marrow and begin producing new, healthy leukocytes to replace the abnormal cells.

New evidence suggests that bone marrow stem cells may be able to differentiate into cell types that make up tissues outside of the blood, such as liver and muscle. Scientists are exploring new uses for these stem cells that go beyond diseases of the blood.

While most blood stem cells reside in the bone marrow, a small number are present in the bloodstream. These peripheral blood stem cells, or PBSCs, can be used just like bone marrow stem cells to treat leukemia, other cancers and various blood disorders.

Since they can be obtained from drawn blood, PBSCs are easier to collect than bone marrow stem cells, which must be extracted from within bones. This makes PBSCs a less invasive treatment option than bone marrow stem cells. PBSCs are sparse in the bloodstream, however, so collecting enough to perform a transplant can pose a challenge.

Newborn infants no longer need their umbilical cords, so they have traditionally been discarded as a by-product of the birth process. In recent years, however, the stem-cellrich blood found in the umbilical cord has proven useful in treating the same types of health problems as those treated using bone marrow stem cells and PBSCs.

See original here:
Stem Cells In Use - Learn Genetics

Posted in Stell Cell Genetics | Comments Off on Stem Cells In Use – Learn Genetics

Stell Cell Research Stem Cell Clinic

Posted: May 31, 2015 at 5:41 pm

The potential therapeutic benefits of HESC research provide strong grounds in favor of the research. If looked at from a strictly consequentialist perspective, its almost certainly the case that the potential health benefits from the research outweigh the loss of embryos involved and whatever suffering results from that loss for persons who want to protect embryos. However, most of those who oppose the research argue that the constraints against killing innocent persons to promote social utility apply to human embryos. Thus, as long as we accept non-consequentialist constraints on killing persons, those supporting HESC research must respond to the claim that those constraints apply to human embryos.

In its most basic form, the central argument supporting the claim that it is unethical to destroy human embryos goes as follows: It is morally impermissible to intentionally kill innocent human beings; the human embryo is an innocent human being; therefore it is morally impermissible to intentionally kill the human embryo. It is worth noting that this argument, if sound, would not suffice to show that all or even most HESC research is impermissible, since most investigators engaged in HESC research do not participate in the derivation of HESCs but instead use cell lines that researchers who performed the derivation have made available. To show that researchers who use but do not derive HESCs participate in an immoral activity, one would further need to establish their complicity in the destruction of embryos. We will consider this issue in section 2. But for the moment, let us address the argument that it is unethical to destroy human embryos.

A premise of the argument against killing embryos is that human embryos are human beings. The issue of when a human being begins to exist is, however, a contested one. The standard view of those who oppose HESC research is that a human being begins to exist with the emergence of the one-cell zygote at fertilization. At this stage, human embryos are said to be whole living member[s] of the species homo sapiens [which] possess the epigenetic primordia for self-directed growth into adulthood, with their determinateness and identity fully intact (George & Gomez-Lobo 2002, 258). This view is sometimes challenged on the grounds that monozygotic twinning is possible until around days 1415 of an embryos development (Smith & Brogaard 2003). An individual who is an identical twin cannot be numerically identical to the one-cell zygote, since both twins bear the same relationship to the zygote, and numerical identity must satisfy transitivity. That is, if the zygote, A, divides into two genetically identical cell groups that give rise to identical twins B and C, B and C cannot be the same individual as A because they are not numerically identical with each other. This shows that not all persons can correctly assert that they began their life as a zygote. However, it does not follow that the zygote is not a human being, or that it has not individuated. This would follow only if one held that a condition of an entitys status as an individual human being is that it be impossible for it to cease to exist by dividing into two or more entities. But this seems implausible. Consider cases in which we imagine adult humans undergoing fission (for example, along the lines of Parfits thought experiments, where each half of the brain is implanted into a different body) (Parfit 1984). The prospect of our going out of existence through fission does not pose a threat to our current status as distinct human persons. Likewise, one might argue, the fact that a zygote may divide does not create problems for the view that the zygote is a distinct human being.

There are, however, other grounds on which some have sought to reject that the early human embryo is a human being. According to one view, the cells that comprise the early embryo are a bundle of homogeneous cells that exist in the same membrane but do not form a human organism because the cells do not function in a coordinated way to regulate and preserve a single life (Smith & Brogaard 2003, McMahan 2002). While each of the cells is alive, they only become parts of a human organism when there is substantial cell differentiation and coordination, which occurs around day-16 after fertilization. Thus, on this account, disaggregating the cells of the 5-day embryo to derive HESCs does not entail the destruction of a human being.

This account is subject to dispute on empirical grounds. That there is some intercellular coordination in the zygote is revealed by the fact that the development of the early embryo requires that some cells become part of the trophoblast while others become part of the inner cell mass. Without some coordination between the cells, there would be nothing to prevent all cells from differentiating in the same direction (Damschen, Gomez-Lobo and Schonecker 2006). The question remains, though, whether this degree of cellular interaction is sufficient to render the early human embryo a human being. Just how much intercellular coordination must exist for a group of cells to constitute a human organism cannot be resolved by scientific facts about the embryo, but is instead an open metaphysical question (McMahan 2007a).

Suppose that the 5-day human embryo is a human being. On the standard argument against HESC research, membership in the species Homo sapiens confers on the embryo a right not to be killed. This view is grounded in the assumption that human beings have the same moral status (at least with respect to possessing this right) at all stages of their lives.

Some accept that the human embryo is a human being but argue that the human embryo does not have the moral status requisite for a right to life. There is reason to think that species membership is not the property that determines a beings moral status. We have all been presented with the relevant thought experiments, courtesy of Disney, Orwell, Kafka, and countless science fiction works. The results seem clear: we regard mice, pigs, insects, aliens, and so on, as having the moral status of persons in those possible worlds in which they exhibit the psychological and cognitive traits that we normally associate with mature human beings. This suggests that it is some higher-order mental capacity (or capacities) that grounds the right to life. While there is no consensus about the capacities that are necessary for the right to life, some of the capacities that have been proposed include reasoning, self-awareness, and agency (Kuhse & Singer 1992, Tooley 1983, Warren 1973).

The main difficulty for those who appeal to such mental capacities as the touchstone for the right to life is that early human infants lack these capacities, and do so to a greater degree than many of the nonhuman animals that most deem it acceptable to kill (Marquis 2002). This presents a challenge for those who hold that the non-consequentialist constraints on killing human children and adults apply to early human infants. Some reject that these constraints apply to infants, and allow that there may be circumstances where it is permissible to sacrifice infants for the greater good (McMahan 2007b). Others argue that, while infants do not have the intrinsic properties that ground a right to life, we should nonetheless treat them as if they have a right to life in order to promote love and concern towards them, as these attitudes have good consequences for the persons they will become (Benn 1973, Strong 1997).

Some claim that we can reconcile the ascription of a right to life to all humans with the view that higher order mental capacities ground the right to life by distinguishing between two senses of mental capacities: immediately exercisable capacities and basic natural capacities. (George and Gomez-Lobo 2002, 260). According to this view, an individuals immediately exercisable capacity for higher mental functions is the actualization of natural capacities for higher mental functions that exist at the embryonic stage of life. Human embryos have a rational nature, but that nature is not fully realized until individuals are able to exercise their capacity to reason. The difference between these types of capacity is said to be a difference between degrees of development along a continuum. There is merely a quantitative difference between the mental capacities of embryos, fetuses, infants, children, and adults (as well as among infants, children, and adults). And this difference, so the argument runs, cannot justify treating some of these individuals with moral respect while denying it to others.

Given that a human embryo cannot reason at all, the claim that it has a rational nature has struck some as tantamount to asserting that it has the potential to become an individual that can engage in reasoning (Sagan & Singer 2007). But an entitys having this potential does not logically entail that it has the same status as beings that have realized some or all of their potential (Feinberg 1986). Moreover, with the advent of cloning technologies, the range of entities that we can now identify as potential persons arguably creates problems for those who place great moral weight on the embryos potential. A single somatic cell or HESC can in principle (though not yet in practice) develop into a mature human being under the right conditionsthat is, where the cells nucleus is transferred into an enucleated egg, the new egg is electrically stimulated to create an embryo, and the embryo is transferred to a womans uterus and brought to term. If the basis for protecting embryos is that they have the potential to become reasoning beings, then, some argue, we have reason to ascribe a high moral status to the trillions of cells that share this potential and to assist as many of these cells as we reasonably can to realize their potential (Sagan & Singer 2007, Savulescu 1999). Because this is a stance that we can expect nearly everyone to reject, its not clear that opponents of HESC research can effectively ground their position in the human embryos potential.

See the original post:
Stell Cell Research Stem Cell Clinic

Posted in Stell Cell Genetics | Comments Off on Stell Cell Research Stem Cell Clinic

Genetic Engineering Advantages & Disadvantages Biology …

Posted: May 31, 2015 at 5:41 pm

During the latter stage stages of the 20th century, man harnessed the power of the atom, and not long after, soon realised the power of genes. Genetic engineering is going to become a very mainstream part of our lives sooner or later, because there are so many possibilities advantages (and disadvantages) involved. Here are just some of the advantages :

Of course there are two sides to the coin, here are some possible eventualities and disadvantages.

Genetic engineering may be one of the greatest breakthroughs in recent history alongside the discovery of the atom and space flight, however, with the above eventualities and facts above in hand, governments have produced legislation to control what sort of experiments are done involving genetic engineering. In the UK there are strict laws prohibiting any experiments involving the cloning of humans. However, over the years here are some of the experimental breakthroughs made possible by genetic engineering.

Genetic engineering has been impossible until recent times due to the complex and microscopic nature of DNA and its component nucleotides. Through progressive studies, more and more in this area is being made possible, with the above examples only showing some of the potential that genetic engineering shows.

For us to understand chromosomes and DNA more clearly, they can be mapped for future reference. More simplistic organisms such as fruit fly (Drosophila) have been chromosome mapped due to their simplistic nature meaning they will require less genes to operate. At present, a task named the Human Genome Project is mapping the human genome, and should be completed in the next ten years.

The process of genetic engineering involves splicing an area of a chromosome, a gene, that controls a certain characteristic of the body. The enzyme endonuclease is used to split a DNA sequence and split the gene from the rest of the chromosome. For example, this gene may be programmed to produce an antiviral protein. This gene is removed and can be placed into another organism. For example, it can be placed into a bacteria, where it is sealed into the DNA chain using ligase. When the chromosome is once again sealed, the bacteria is now effectively re-programmed to replicate this new antiviral protein. The bacteria can continue to live a healthy life, though genetic engineering and human intervention has actively manipulated what the bacteria actually is. No doubt there are advantages and disadvantages, and this whole subject area will become more prominent over time.

The next page returns the more natural circumstances of genetic diversity.

See the original post: Genetic Engineering Advantages & Disadvantages Biology

Tags: a-actually-is-, a-healthy-life, a-task-named, a-will-become, atom, chromosome, experimental, named-the-human, with-the-above

This entry was posted on May 28, 2015 at 6:43 pm and is filed under Genetic Engineering. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |

Continued here:
Genetic Engineering Advantages & Disadvantages Biology ...

Posted in Stell Cell Genetics | Comments Off on Genetic Engineering Advantages & Disadvantages Biology …

Embryonic stem cell – Wikipedia, the free encyclopedia

Posted: May 31, 2015 at 5:41 pm

Embryonic stem cells (ES cells) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage preimplantation embryo.[1][2] Human embryos reach the blastocyst stage 45 days post fertilization, at which time they consist of 50150 cells. Isolating the embryoblast or inner cell mass (ICM) results in destruction of the blastocyst, which raises ethical issues, including whether or not embryos at the pre-implantation stage should be considered to have the same moral status as more developed human beings.[3][4]

Human ES cells measure approximately 14 m while mouse ES cells are closer to 8 m.[5]

Embryonic stem cells, derived from the blastocyst stage early mammalian embryos, are distinguished by their ability to differentiate into any cell type and by their ability to propagate. Embryonic stem cell's properties include having a normal karyotype, maintaining high telomerase activity, and exhibiting remarkable long-term proliferative potential.

Embryonic stem cells of the inner cell mass are pluripotent, that is, they are able to differentiate to generate primitive ectoderm, which ultimately differentiates during gastrulation into all derivatives of the three primary germ layers: ectoderm, endoderm, and mesoderm. These include each of the more than 220 cell types in the adult body. Pluripotency distinguishes embryonic stem cells from adult stem cells found in adults; while embryonic stem cells can generate all cell types in the body, adult stem cells are multipotent and can produce only a limited number of cell types. If the pluripotent differentiation potential of embryonic stem cells could be harnessed in vitro, it might be a means of deriving cell or tissue types virtually to order. This would provide a radical new treatment approach to a wide variety of conditions where age, disease, or trauma has led to tissue damage or dysfunction.

Additionally, under defined conditions, embryonic stem cells are capable of propagating themselves indefinitely in an undifferentiated state and have the capacity when provided with the appropriate signals to differentiate, presumably via the formation of precursor cells, to almost all mature cell phenotypes.[6] This allows embryonic stem cells to be employed as useful tools for both research and regenerative medicine, because they can produce limitless numbers of themselves for continued research or clinical use.

Because of their plasticity and potentially unlimited capacity for self-renewal, Embryonic stem cell therapies have been proposed for regenerative medicine and tissue replacement after injury or disease. Diseases that could potentially be treated by pluripotent stem cells include a number of blood and immune-system related genetic diseases, cancers, and disorders; juvenile diabetes; Parkinson's; blindness and spinal cord injuries. Besides the ethical concerns of stem cell therapy (see stem cell controversy), there is a technical problem of graft-versus-host disease associated with allogeneic stem cell transplantation. However, these problems associated with histocompatibility may be solved using autologous donor adult stem cells, therapeutic cloning. The therapeutic cloning done by a method called somatic cell nuclear transfer (SCNT) may be advantageous against mitochondrial DNA (mtDNA) mutated diseases.[7] Stem cell banks or more recently by reprogramming of somatic cells with defined factors (e.g. induced pluripotent stem cells). Embryonic stem cells provide hope that it will be possible to overcome the problems of donor tissue shortage and also, by making the cells immunocompatible with the recipient. Other potential uses of embryonic stem cells include investigation of early human development, study of genetic disease and as in vitro systems for toxicology testing.

According to a 2002 article in PNAS, "Human embryonic stem cells have the potential to differentiate into various cell types, and, thus, may be useful as a source of cells for transplantation or tissue engineering."[8]

Current research focuses on differentiating ES into a variety of cell types for eventual use as cell replacement therapies (CRTs). Some of the cell types that have or are currently being developed include cardiomyocytes (CM), neurons, hepatocytes, bone marrow cells, islet cells and endothelial cells.[9] However, the derivation of such cell types from ESs is not without obstacles and hence current research is focused on overcoming these barriers. For example, studies are underway to differentiate ES in to tissue specific CMs and to eradicate their immature properties that distinguish them from adult CMs.[10] Lately,two teams in San Diegos ViaCyte and Bostons Harvard University successively announced their progress on embryonic stem cells for curing diabetes, which was suggested to be the beginning of the golden age of stem cell therapeutics.[11]

Besides in the future becoming an important alternative to organ transplants, ES are also being used in field of toxicology and as cellular screens to uncover new chemical entities (NCEs) that can be developed as small molecule drugs. Studies have shown that cardiomyocytes derived from ES are validated in vitro models to test drug responses and predict toxicity profiles.[9] ES derived cardiomyocytes have been shown to respond to pharmacological stimuli and hence can be used to assess cardiotoxicity like Torsades de Pointes.[12]

ES-derived hepatocytes are also useful models that could be used in the preclinical stages of drug discovery. However, the development of hepatocytes from ES has proven to be challenging and this hinders the ability to test drug metabolism. Therefore, current research is focusing on establishing fully functional ES-derived hepatocytes with stable phase I and II enzyme activity.[13]

Read the original here:
Embryonic stem cell - Wikipedia, the free encyclopedia

Posted in Stell Cell Genetics | Comments Off on Embryonic stem cell – Wikipedia, the free encyclopedia

Page 1,785«..1020..1,7841,7851,7861,787..1,7901,800..»